Climb Bio, Inc.

CLYM

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management33.0%Dec 15, 2025

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 600,946Value: $2.4M

# Signal Note: Driehaus Capital Initiates CLYM Position Growth-focused Driehaus established a $2.4M stake in Climb Bio, a pre-clinical stage biotech focused on epigenetic therapies for cancer and neurological diseases. The entry suggests conviction in Climb's platform technology ahead of anticipated IND-enabling studies and regulatory catalysts, though the company remains early-stage with limited clinical validation and near-term value inflection points unclear.

RA Capital ManagementNEWFeb 17, 2026

More CLYM Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN2 funds SION2 funds NUVL2 funds PEPG2 funds RNA2 funds INSP2 funds JBIO2 funds ASND

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RA Capital initiates $77.7M position in Climb Bio (CLYM) RA Capital's new $77.7M stake in Climb Bio signals confidence in the company's lead program, CBL0137, a curaxin in development for liposarcoma and other solid tumors—a rare but addressable market with limited treatment options. The timing aligns with anticipated clinical data readouts expected in 2024-2025 that could validate the mechanism in this difficult-to-treat indication. This represents typical conviction-level sizing for RA Capital in early-to-mid stage oncology assets with differentiated mechanisms.